Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13176296 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2MRGPRX1GBA1OPRM1 | |
| SCHEMBL984621 | 0.80 | HCRTR1 (0.42) | HCRTR1HCRTR2MRGPRX1GBA1OPRM1 | |
| Hydrochloric Acid SCHEMBL1398737 | 0.78 | MRGPRX1 (0.44) | HCRTR1HCRTR2MRGPRX1CACNA1HNPC1 | |
| Hydrochloric Acid SCHEMBL1398738 | 0.78 | MRGPRX1 (0.44) | HCRTR1HCRTR2MRGPRX1CACNA1HNPC1 | |
| SCHEMBL1572333 | 0.77 | HCRTR1 (0.41) | HCRTR1HCRTR2MRGPRX1GBA1OPRM1 | |
| SCHEMBL1572330 | 0.77 | HCRTR1 (0.41) | HCRTR1HCRTR2MRGPRX1GBA1OPRM1 | |
| SCHEMBL13538937 | 0.76 | HTR4 (0.49) | — | |
| SCHEMBL1340659 | 0.76 | MTNR1B (0.43) | GBA1NPC1ALDH1A1 | |
| SCHEMBL3647141 | 0.71 | MRGPRX1 (0.45) | HCRTR1HCRTR2MRGPRX1BRD4 | |
| SCHEMBL1339577 | 0.71 | HCRTR1 (0.49) | HCRTR1HCRTR2CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885MRGPRX1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.